Developability Assessment During the Selection of Novel Therapeutic Antibodies
Top Cited Papers
- 1 June 2015
- journal article
- review article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 104 (6) , 1885-1898
Abstract
No abstract availableKeywords
Funding Information
- Roche
This publication has 129 references indexed in Scilit:
- Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodiesProtein Science, 2013
- Specific Ion–Protein Interactions Dictate Solubility Behavior of a Monoclonal Antibody at Low Salt ConcentrationsMolecular Pharmaceutics, 2012
- Chemical Modifications in Aggregates of Recombinant Human Insulin Induced by Metal-Catalyzed Oxidation: Covalent Cross-Linking via Michael Addition to Tyrosine Oxidation ProductsPharmaceutical Research, 2012
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodiesProceedings of the National Academy of Sciences, 2011
- Controlling glycation of recombinant antibody in fed‐batch cell culturesBiotechnology and Bioengineering, 2011
- Characterization and Comparison of Disulfide Linkages and Scrambling Patterns in Therapeutic Monoclonal Antibodies: Using LC-MS with Electron Transfer DissociationAnalytical Chemistry, 2011
- Effective charge measurements reveal selective and preferential accumulation of anions, but not cations, at the protein surface in dilute salt solutionsProtein Science, 2011
- Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibodyProtein Science, 2009
- Enrichment and Analysis of Nonenzymatically Glycated Peptides: Boronate Affinity Chromatography Coupled with Electron-Transfer Dissociation Mass SpectrometryJournal of Proteome Research, 2007
- SVMHC: a server for prediction of MHC-binding peptidesNucleic Acids Research, 2006